Cardiovascular Drugs and Therapy

, Volume 24, Issue 4, pp 359–367 | Cite as

Smoking Cessation–Recent Advances

  • John J. McNeil
  • Loretta Piccenna
  • Lisa L. Ioannides-Demos
Article
First Online:

Abstract

Background

Smoking continues to be a major contributor to the burden of disease across the world although there has been a decrease in some developed countries such as USA and Australia. In countries of South-East Asia with a high prevalence of smoking, the incidence of tobacco-related diseases will continue to increase.

Methods

We reviewed the literature in relation to the pharmacology of nicotine, the measures used to determine the efficacy of anti-smoking therapies, and the randomised controlled trials and systematic reviews of pharmacotherapies published between 2004 and 2010. We focused primarily on the three first line therapies that are currently available: nicotine replacement therapy (NRT), bupropion and varenicline.

Results

Randomised controlled trials and meta-analyses have demonstrated that single therapy with either NRT, bupropion or varenicline are all more effective than placebo for smoking cessation. Abstinence rates for monotherapies varies from 13.3% to 19% for NRT compared to 7.5% to 14% for placebo, 19% to 19.7% for bupropion versus 10.9% to 11% for placebo and 25.5% to 25.6% for varenicline versus 11.2% to 14.8% for placebo. Of current therapies varenicline appears to be more effective at achieving abstinence. Some combination therapies with one or two formulations of NRT or NRT plus bupropion have demonstrated superior results to monotherapy. To date there are no randomised controlled trials of varenicline in combination with NRT or bupropion.

Conclusion

Further studies are required to address the uncertainty that exists on the most appropriate duration of therapy as well as the effectiveness and safety of combination pharmacotherapy. Post-marketing surveillance continues to play an important role in monitoring the adverse effects events associated with these therapies.

Key words

Smoking cessation Pharmacotherapy Nicotine replacement therapy Varenicline Bupropion Vaccines 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Winstanley M, White V. Chapter 1. Trends in the prevalence of smoking. In: Scollo MM, Winstanley MH, eds. Tobacco in Australia: Facts and Issues. 3 rd ed. Melbourne: Cancer Council Victoria; 2008. Accessed 22 December 2010 at http://www.tobaccoinaustralia.org.au/chapter-1-prevalence.
  2. 2.
    Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults—United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:1221–6.Google Scholar
  3. 3.
    WHO (World Health Organisation). Prevalence of current tobacco use among adults aged ≥ 15 years. Accessed 27 January 2010 at http://www.who.int/whosis/en/index.html
  4. 4.
    WHO (World Health Organisation). Report on the Global Tobacco Epidemic, 2009. Implementing smoke-free environments. Appendix VII: Age-Standardized Prevalence Estimates for Smoking, 2006. Accessed 27 January 2009 at www.who.int/tobacco/mpower/en
  5. 5.
    Gu D, Kelly TN, Wu X, Chen J, Samet JM, Huang J, et al. Mortality attributable to smoking in China. N Engl J Med. 2009;360:150–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Peto R, Lopez AD. The future worldwide health effects of current smoking patterns. In: Koop CE, Pearson CE, Schwarz MR, editors. Global health in the 21st century. New York: Jossey-Bass; 2000.Google Scholar
  7. 7.
    Frishman WH. Smoking cessation pharmacotherapy. Ther Adv Cardiovasc Dis. 2009;3:287–308.CrossRefPubMedGoogle Scholar
  8. 8.
    SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tobacco Res. 2002;4:149–59.CrossRefGoogle Scholar
  9. 9.
    Royal College of Physicians of London. Nicotine Addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians, London. February 2000 (Accessed September 2009 at http://www.rcplondon.ac.uk/pubs/brochure.aspx?e=131)
  10. 10.
    Hubbard R, Lewis S, Smith C, Godfrey C, Smeeth L, Farrington P, et al. Use of nicotine replacement therapy and the risk of acute myocardial infarction, stroke, and death. Tobacco Control. 2005;14:416–21.CrossRefPubMedGoogle Scholar
  11. 11.
    Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD000146.Google Scholar
  12. 12.
    Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3, CD000146.Google Scholar
  13. 13.
    Schnoll RA et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med. 2010;152:144.PubMedGoogle Scholar
  14. 14.
    Roddy E. ABC of smoking cessation. Bupropion and other non-nicotine pharmacotherapies. BMJ. 2004;328:509–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD000031.Google Scholar
  16. 16.
    Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009; 1:CD003999.Google Scholar
  17. 17.
    FDA. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics). Drug Safety Newsletter. 2009;2:1–4.Google Scholar
  18. 18.
    Kuehn BM. Varenicline gets stronger warnings about psychiatric problems, vehicle crashes. JAMA. 2009;302:834.CrossRefPubMedGoogle Scholar
  19. 19.
    Faessel HM, Smith BJ, Gibbs MA, Gobey JS, Clark DJ, Burstein AH. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol. 2006;46:991–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist varenicline in healthy smokers. J Clin Pharmacol. 2006;46:1439–48.CrossRefPubMedGoogle Scholar
  21. 21.
    Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol. 2006;46:1234–40.CrossRefPubMedGoogle Scholar
  22. 22.
    Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006;34:121–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009;31:463–91.CrossRefPubMedGoogle Scholar
  24. 24.
    Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 3. Art. No: CD006103.Google Scholar
  25. 25.
    Eisenberg MJ, Filion KB, Yavin D, Bélisle P, Mottillo S, Joseph L, et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ. 2008;179:135–44.PubMedGoogle Scholar
  26. 26.
    Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Harris DS, Anthenelli RM. Expanding treatment of tobacco dependence. Curr Psychiatry Rep. 2005;7:344–51.CrossRefPubMedGoogle Scholar
  29. 29.
    Moore TJ, Cohen MR, Furberg CD. Strong Safety Signal Seen for New Varenicline Risks. Report. The Institute of Safe Medication Practices, Horsham, PA, USA. May 2008. Accessed 22 December 2009 at www.ismp.org/docs/vareniclineStudy.asp
  30. 30.
    Moore TJ, Furberg CD. Risk of psychiatric side effects with varenicline. BMJ. 2009;339:b4964.CrossRefPubMedGoogle Scholar
  31. 31.
    Harrison-Woolrych M. Varenicline and suicide. Safety data from New Zealand. BMJ. 2009;339:b5654.CrossRefPubMedGoogle Scholar
  32. 32.
    Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction. 2008;103:146–54.CrossRefPubMedGoogle Scholar
  33. 33.
    Evins AE, Goff DC. Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008;69:1016.CrossRefPubMedGoogle Scholar
  34. 34.
    Purvis TL, Mambourg SE, Balvanz TM, Magallon HE, Pham RH. Safety and effectiveness of varenicline in a veteran population with a high prevalence of mental illness. Ann Pharmacother 2009; 43.Google Scholar
  35. 35.
    McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA, et al. Mood side-effects and smoking outcomes among persons with or without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24:563–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ. 2009;339:b3805.CrossRefPubMedGoogle Scholar
  37. 37.
    Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, van Melle G, et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS. 2008;3:e2547.Google Scholar
  38. 38.
    Shah SD, Wilken LA, Winkler SR, Lin SJ. Systematic review and meta-analysis of combination therapy for smoking cessation. J Am Pharm Assoc. 2008;48:659–65.CrossRefGoogle Scholar
  39. 39.
    Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. Randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66:1253–62.CrossRefPubMedGoogle Scholar
  40. 40.
    Steinberg M, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically Ill smokers. A randomized trial. Ann Intern Med. 2009;150:447–54.PubMedGoogle Scholar
  41. 41.
    Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med. 2009;169:2148–55.CrossRefPubMedGoogle Scholar
  42. 42.
    Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(16). (Assessed November 2009 at http://www.hta.nhs.uk/pdfexecs/summ616.pdf )
  43. 43.
    Keating GM, Lyseng-Williamson KA. Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation. PharmacoEconomics. 2010;28:231–54.CrossRefPubMedGoogle Scholar
  44. 44.
    Hammond EC, Horn D. Smoking and death rates. Report on forty-four months of follow up of 187,783 men. JAMA. 1958;166:1159–72–1294–308.Google Scholar
  45. 45.
    Quaak M, van Schayck CP, Knaapen AM, van Schooten FJ. Genetic variation as a predictor of smoking cessation success. A promising preventive and intervention tool for chronic respiratory diseases? Eur Respir J. 2009;33:468–80.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • John J. McNeil
    • 1
  • Loretta Piccenna
    • 1
  • Lisa L. Ioannides-Demos
    • 1
  1. 1.Department of Epidemiology & Preventive Medicine, School of Public Health & Preventive Medicine, Alfred HospitalMonash UniversityMelbourneAustralia

Personalised recommendations